Teva (TEVA) CFO offloads 345,810 shares in Rule 10b5-1 sale

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd executive vice president and chief financial officer Eliyahu Sharon Kalif sold 345,810 Ordinary Shares in an open-market transaction on February 26, 2026, at a weighted average price of $33.6448 per share.

After this sale, he directly held 57,478 Ordinary Shares. The shares may be represented by American Depositary Shares on a one-for-one basis, and the sale was carried out under a Rule 10b5-1 trading plan adopted on November 26, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalif Eliyahu Sharon

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	02/26/2026		S(2)		345,810	D	$33.6448(3)	57,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.57 to $33.86, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teva (TEVA) report for Eliyahu Sharon Kalif?

Teva reported that executive vice president and chief financial officer Eliyahu Sharon Kalif sold 345,810 Ordinary Shares in an open-market transaction on February 26, 2026, at a weighted average price of $33.6448 per share, leaving him with 57,478 Ordinary Shares directly held.

At what price did the Teva (TEVA) CFO sell his Ordinary Shares?

The Teva chief financial officer sold his 345,810 Ordinary Shares at a weighted average price of $33.6448 per share. Footnotes state the sales occurred in multiple trades between $33.57 and $33.86, with full price breakdowns available upon request to the company or regulators.

How many Teva (TEVA) shares does the CFO hold after this Form 4 sale?

Following the February 26, 2026 sale, the Teva chief financial officer directly holds 57,478 Ordinary Shares. This post-transaction ownership figure is disclosed in the Form 4 and reflects his remaining direct stake after selling 345,810 Ordinary Shares in the open-market transaction.

Was the Teva (TEVA) CFO’s share sale under a Rule 10b5-1 trading plan?

Yes. The filing explains the sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, helping separate personal transactions from day-to-day corporate developments.

Can Teva (TEVA) Ordinary Shares be held as American Depositary Shares (ADS)?

Yes. Footnotes clarify that Teva Ordinary Shares may be represented by American Depositary Shares, with each ADS currently corresponding to one Ordinary Share. This one-for-one relationship helps investors hold Teva equity through depositary receipts that mirror the underlying Ordinary Share ownership structure.

What trading range is disclosed for the Teva (TEVA) CFO’s share sale?

The weighted average sale price was $33.6448, but the filing notes individual trades occurred between $33.57 and $33.86 per share. The reporting person has committed to provide detailed breakdowns of the number of shares sold at each separate price level upon request to relevant parties.